International Multicentric Study ARON-1
Latest Information Update: 16 Jul 2024
Price :
$35 *
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Oct 2023 Planned End Date changed from 1 Nov 2022 to 31 Dec 2024.
- 12 Oct 2023 Planned primary completion date changed from 30 Sep 2022 to 1 Jun 2024.
- 30 Aug 2022 Status changed from not yet recruiting to recruiting.